Prosecution Insights
Last updated: November 20, 2026
Application No. 18/601,773

CARDIOSPHERE-DERIVED CELLS AND THEIR EXTRACELLULAR VESICLES FOR TREATMENT AND PREVENTION OF CANCER

Final Rejection §103
Filed
Mar 11, 2024
Priority
Aug 04, 2017 — provisional 62/541,584 +2 more
Examiner
MOSS, NATALIE M
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cedars-Sinai Medical Center
OA Round
6 (Final)
31%
Grant Probability
At Risk
7-8
OA Rounds
1y 2m
Est. Remaining
48%
With Interview

Examiner Intelligence

Grants only 31% of cases
31%
Career Allowance Rate
161 granted / 525 resolved
-29.3% vs TC avg
Strong +17% interview lift
Without
With
+16.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
57 currently pending
Career history
607
Total Applications
across all art units

Statute-Specific Performance

§101
7.9%
-32.1% vs TC avg
§103
45.0%
+5.0% vs TC avg
§102
13.5%
-26.5% vs TC avg
§112
29.1%
-10.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 525 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 24 March 2026 has been entered. DETAILED OFFICE ACTION This Office Action is in response to the papers filed on 24 March 2026. CLAIMS UNDER EXAMINATION Claims 1, 5-6, 9-12, 17 and 22 have been examined on their merits. PRIORITY The Applicant claims priority to Provisional Application 62/541584, filed on 04 August 2017. The disclosure provides support for peritumoral administration (see page 3, line 15). It does not provide support for intratumoral injection, or injection into a tumor. PCT/US2018/044956, 16/635,142 and the instant specification provide support for infusion “into or near a tumor” (hence, intratumoral or peritumoral) at [0095]. WITHDRAWN OBJECTION The objection to claim 9 has been withdrawn due to claim amendment. WITHDRAWN REJECTIONS The previous rejections have been withdrawn due to claim amendment. REJECTIONS New rejections have been necessitated by claim amendment.. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1, 5 and 9-12 are rejected under 35 U.S.C. 103 as being unpatentable over Marban et al. (previously cited; Exosomes and Micro-Ribonucleic Acid For Tissue Regeneration (US20150203844) in view of Marban et al. (previously cited; Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells. WO2016057560 14 April 2016). Marban (2015) teaches a method of repairing and/or regenerating damaged or diseased tissue comprising administering compositions comprising exosomes (hence, an extracellular vesicle; Abstract). The exosomes can be used to treat tissue damage caused by chronic diseases ([0012]) ([0076]). Cancer is identified as a chronic disease ([0012] [0076]). Marban teaches “exosomes can be administered to treat a variety of cancerous target tissues” and tumors ([0077]). Exosomes are secreted by cardiosphere-derived cells (CDCs) ([0008] [0011] [0068]). The protein content of exosomes is suited for repair or regeneration of damaged or diseased cells ([0066]). The protein carried by exosomes can be administered to a subject in need of tissue repair ([0068]). The exosomes can be harvested and the proteins can be collected from the exosome ([0068]). The dose administered ranges from about 1.0×105 to about 1.0×109 exosomes ([0073]). The exosome dose is administered on a per kilogram basis ([0073]). Marban teaches direct injection ([0071]). The exosomes can be delivered “directly to a central portion of the damaged or diseased tissue (e.g., to the central portion of a tumor…)” ([0072]). This is interpreted to be intratumoral administration. Marban is silent regarding the amount of EV protein delivered by body weight of the subject. Marban does not teach intratumoral injection with sufficient specificity to anticipate the claim. Marban et al. (WO2016) teach a therapeutic application of cardiosphere-derived exosomes (Abstract). The art teaches treating a subject for a disease and/or condition involving tissue damage or dysfunction (See page 36 lines 22-25). Marban teaches the tissue damage can be caused by cancer (see page 40, lines 23-24). Exosomes contain a biological milieu of different proteins (page 17, lines 19-24). Marban teaches the exosome quantity may be defined by protein quantity, such as dosages including 1-10, 10-25, 25-50, 50-75, 75-100, or 100 or more mg exosome protein. (See page 26, lines 35-39; page 38 lines 9-11). Examiner notes 1 mg is 1000 micrograms (1 milligram multiplied by 1000). It would have been obvious to combine the teachings of the prior art by administering at least 7 µg EV protein per gram of body weight of a subject. Marban teaches administering exosomes to treat dysfunctional cells and tissues caused by cancer and Marban (WO 2016) the dosage of exosome used to treat dysfunctional and damaged tissue can be defined by protein quantity, and includes dosages of 1000 microgram or more protein. One would have been motivated to administer exosome protein since Marban teaches the protein content of exosomes is suited for repair or regeneration of damaged or diseased cells and tissue. Marban teaches the exosome dose is administered on a per kilogram basis. The skilled artisan would optimize the dosage by weight to obtain the desired therapeutic effect. One would have had a reasonable expectation of success since Marban (2016) teaches the exosome dose can be defined by the amount of protein delivered. One would have expected similar results since both references treat damaged and dysfunctional cells and tissue caused by cancer. Because the claimed dosage is rendered obvious, it would decrease cancer in a subject as claimed. It would have been obvious to administer via intratumoral injection. One would have been motivated to do so for direct injection of exosomes to the tumor of a patient. One would have had a reasonable expectation of success since Marban teaches exosomes can be administered to the central portion of a tumor. See KSR E. Therefore claim 1 is rendered obvious. Intratumoral injection is rendered obvious on the grounds stated above. Claim 5 is included in this rejection. Marban teaches delivery of exosomes directly to a tumor (supra). Because the art treats a tumor with the claimed composition, it would be expected to have the effect recited in claim 9. Marban teaches administration by injection ([0071]). Marban teaches delivery of multiple doses ([0074]). Therefore administration of two or more injections is rendered obvious. Therefore claim 10 is included in this rejection. Marban teaches the regenerative cells may be human ([0009]). The art teaches the cells can be allogenic to the individual ([0009]). Therefore claim 11 is included in this rejection. Marban teaches isolation of exosomes in serum free conditions ([0031]). Therefore claim 12 is included in this rejection. Therefore Applicant’s Invention is rendered obvious as claimed. Claims 1, 6, 9-12 and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Marban et al. (previously cited; Exosomes and Micro-Ribonucleic Acid For Tissue Regeneration (US20150203844 2015) in view of Marban et al. (previously cited; Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells. WO2016057560 14 April 2016) and Batrakova et al. (previously cited; Biological agent-exosome compositions and uses thereof. US20200297631 with benefit of Provisional applicaition62/315389 30 March 2016). Regarding claim 1: The teachings of Marban 2015 are reiterated. Marban teaches administration to a damaged tissue. The art teaches administration to a tumor. The art teaches injection. The art does not explicitly teach peritumoral injection. Marban is silent regarding the amount of EV protein delivered by body weight of the subject. The teachings of Marban 2016 are reiterated. Batrakova et al. teach methods of delivering a composition comprising exosomes and biological agents to cells and subjects ([0003]). Exosomes allow delivery to cancer cells ([0007]). The art teaches formulation for direct organ injection into a tumor or the tissue surrounding a tumor ([0176]). The art teaches it is desirable to deliver the formulation locally to avoid any side effects associated with systemic administration. Local administration can be accomplished by direct injection at the desired treatment site, by introduction intravenously at a site near a desired treatment site (e.g., into a vessel that feeds a treatment site) ([0176]). It would have been obvious to combine the teachings of the prior art by administering at least 7 µg EV protein per gram of body weight of a subject. Marban teaches administering exosomes to treat dysfunctional cells and tissues caused by cancer and Marban (WO 2016) the dosage of exosome used to treat dysfunctional and damaged tissue can be defined by protein quantity, and includes dosages of 1000 microgram or more protein. One would have been motivated to administer exosome protein since Marban teaches the protein content of exosomes is suited for repair or regeneration of damaged or diseased cells and tissue. Marban teaches the exosome dose is administered on a per kilogram basis. The skilled artisan would optimize the dosage by weight to obtain the desired therapeutic effect. One would have had a reasonable expectation of success since Marban (2016) teaches the exosome dose can be defined by the amount of protein delivered. One would have expected similar results since both references treat damaged and dysfunctional cells and tissue caused by cancer. Because the claimed dosage is rendered obvious, it would decrease cancer in a subject as claimed. It would have been obvious to administer via peritumoral injection. Marban teaches tumoral injection and Batrakova teaches the surrounding tumor microenvironment can be injected. One would use peritumoral injection to avoid systemic side effects as taught by Batrakova. One would have had a reasonable expectation of success since Batrakova teaches exosomes can be administered to the area surrounding a tumor. One would have expected similar results since both references are directed to methods of administering exosomes. Therefore claim 1 is rendered obvious. Peritumoral injection is rendered obvious on the grounds stated above. Claim 6 is included in this rejection. Marban teaches delivery of exosomes directly to a tumor (supra). Because the art treats a tumor with the claimed composition, it would be expected to have the effect recited in claim 9 in a subject with cancer. Therefore claim 9 is included in this rejection. Marban teaches administration by injection ([0071]). Marban teaches delivery of multiple doses ([0074]). Therefore administration of two or more injections is rendered obvious. Therefore claim 10 is included in this rejection. Marban teaches the regenerative cells may be human ([0009]). The art teaches the cells can be allogenic to the individual ([0009]). Therefore claim 11 is included in this rejection. Marban teaches isolation of exosomes in serum free conditions ([0031]). Therefore claim 12 is included in this rejection. Regarding claim 22: It is well known in the art that fibrosarcoma is a soft tissue cancer. Batrakova teaches the disclosed method can be used to treat soft tissue sarcoma ([0120]). It would have been obvious to try treating fibrosarcoma by administered CDC-derived exosomes. Marban teaches exosomes can be used to treat dysfunctional and diseased tissues caused by cancer, and Batrakova teaches soft-tissue sarcomas can be treated with exosomes. One would have had a reasonable expectation of success since Marban teaches the protein content of exosomes is suited for repair or regeneration of damaged or diseased cells. Therefore claim 22 is rendered obvious. Therefore Applicant’s Invention is rendered obvious as claimed. Claim 17 is rejected under 35 U.S.C. 103 as being unpatentable over Marban et al. in view of Marban (WO2016) as recited in the rejection of claim 1, and further in view of Lim et al. (previously cited; Mesenchymal stem cell particles. US20150190430). Claim 1 is rejected on the grounds set forth above. The teachings of the Marban and Marban (WO2016) are reiterated. Marban teaches size exclusion filtration is used in order to collect a particular size (e.g., diameter) of exosome ([0061]). The exosomes can have a diameter of about 5 nm to about 95 nm in diameter ([0013]). Marban is silent regarding the size of the filters used to collect the exosomes. Lim is directed to secreted vesicles or exosomes (Abstract). The art teaches using a 1000 kDa membrane to isolate particles less than 1000 kDa ([0301]). The art teaches using membranes with a 10 kDa MW cut off to concentrate exosomes with a size of 2 nm to 200 nm (see claim 4 of Lim; [0281]). It would have been obvious to use a 1000 kDa and a 10 kDa filter to isolate exosomes. One would have been motivated to do so since Marban isolates exosomes using size exclusion filtration and Lim teaches a 1000 kDa and a 10 kDa filter can be used to isolate exosomes. One would have had a reasonable expectation of success since Marban isolated exosomes 5 nm-95 nm in diameter and Lim teaches size exclusion filtration can be used to isolate exosomes between 2 nm to 200 nm. One would have expected similar results since both references use size exclusion to isolate exosomes. Therefore claim 17 is included in this rejection. Therefore Applicant’s Invention is rendered obvious as claimed. RESPONSE TO APPLICANT’S ARGUMENTS The arguments made in the response filed on 23 March 2026 are acknowledged. The Applicant argues the references do not teach intratumoral or peritumoral administration. New grounds of rejection have been set forth above. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NATALIE MOSS whose telephone number is (571) 270-7439. The examiner can normally be reached on Monday-Friday, 8am-5pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached on (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is (571) 270-8439. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NATALIE M MOSS/ Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Show 6 earlier events
Aug 27, 2025
Non-Final Rejection mailed — §103
Nov 25, 2025
Response Filed
Dec 23, 2025
Final Rejection mailed — §103
Mar 23, 2026
Request for Continued Examination
Mar 25, 2026
Response after Non-Final Action
May 01, 2026
Non-Final Rejection mailed — §103
Sep 01, 2026
Response Filed
Nov 18, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12691148
USE OF PROBIOTICS IN THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS
3y 11m to grant Granted Jul 28, 2026
Patent 12576116
USE OF PROBIOTICS IN THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS
7y 2m to grant Granted Mar 17, 2026
Patent 12115199
Delivery System and Probiotic Composition for Animals and Plants
6y 9m to grant Granted Oct 15, 2024
Patent 12005089
CVS TRANSPLANTATION FOR TREATMENT OF BACTERIAL VAGINOSIS
8y 0m to grant Granted Jun 11, 2024
Patent 11262362
2-HYDROXYGLUTARATE AS A BIOMARKER FOR CHRONIC HYPOXIA
7y 9m to grant Granted Mar 01, 2022
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
31%
Grant Probability
48%
With Interview (+16.9%)
3y 10m (~1y 2m remaining)
Median Time to Grant
High
PTA Risk
Based on 525 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month